Related Experiment Videos
Combination versus sequential single-agent therapy in metastatic breast cancer
David Miles1, Gunter von Minckwitz, Andrew D Seidman
1ICRF Breast Cancer Biology Unit, Guy's and St. Thomas' Hospital, London, UK. d.miles@icrf.icnet.uk
The Oncologist
|November 28, 2002
Summary
For metastatic breast cancer, both combination and sequential therapies are effective. Newer drug combinations offer survival benefits, while sequential therapy may reduce toxicity and improve quality of life, especially for frail patients.
Area of Science:
- Oncology
- Medical Oncology
- Breast Cancer Research
Background:
- The optimal treatment strategy for metastatic breast cancer remains debated.
- Historically, sequential administration of antitumor agents was favored over combination therapy due to concerns about toxicity and efficacy.
- Older combination regimens often provided limited clinical benefit and increased side effects compared to monotherapy.
Purpose of the Study:
- To review and compare clinical trial data on combination versus sequential therapy for metastatic breast cancer.
- To evaluate the efficacy, safety, and quality of life implications of different treatment approaches.
- To discuss the role of treatment heterogeneity in guiding therapeutic decisions.
Main Methods:
- Review of clinical trials comparing combination chemotherapy regimens with sequential single-agent approaches.
- Analysis of data regarding survival outcomes, toxicity profiles, and patient quality of life.
- Consideration of factors influencing treatment choice, such as tumor burden and patient characteristics.
Main Results:
- Newer combination regimens (e.g., paclitaxel/trastuzumab, capecitabine/docetaxel) demonstrate survival advantages over single-agent therapies with manageable safety profiles.
- Combination therapy may be advantageous for patients needing rapid tumor burden reduction.
- Sequential therapy offers optimal single-drug delivery, potentially reducing toxicity and improving quality of life, particularly for elderly or frail patients with slow-growing tumors.
Conclusions:
- Both combination and sequential therapies have established roles in managing metastatic breast cancer.
- Treatment selection requires a flexible approach, considering breast cancer heterogeneity and individual patient factors.
- Evidence supports the use of newer combination regimens for improved survival and sequential therapy for optimized toxicity management and quality of life.